Oncolys Biopharma Inc
TSE:4588
Oncolys Biopharma Inc
Operating Income
Oncolys Biopharma Inc
Operating Income Peer Comparison
Competitive Operating Income Analysis
Latest Figures & CAGR of Competitors
Company | Operating Income | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
O
|
Oncolys Biopharma Inc
TSE:4588
|
Operating Income
-¥1.9B
|
CAGR 3-Years
-5%
|
CAGR 5-Years
-9%
|
CAGR 10-Years
N/A
|
GNI Group Ltd
TSE:2160
|
Operating Income
¥5.2B
|
CAGR 3-Years
44%
|
CAGR 5-Years
55%
|
CAGR 10-Years
N/A
|
|
PeptiDream Inc
TSE:4587
|
Operating Income
¥6.8B
|
CAGR 3-Years
-1%
|
CAGR 5-Years
9%
|
CAGR 10-Years
N/A
|
|
Takara Bio Inc
TSE:4974
|
Operating Income
¥1.5B
|
CAGR 3-Years
-49%
|
CAGR 5-Years
-21%
|
CAGR 10-Years
-2%
|
|
J
|
Japan Tissue Engineering Co Ltd
TSE:7774
|
Operating Income
-¥155.3m
|
CAGR 3-Years
18%
|
CAGR 5-Years
17%
|
CAGR 10-Years
17%
|
S
|
StemRIM Inc
TSE:4599
|
Operating Income
¥142.4m
|
CAGR 3-Years
-30%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
See Also
What is Oncolys Biopharma Inc's Operating Income?
Operating Income
-1.9B
JPY
Based on the financial report for Dec 31, 2023, Oncolys Biopharma Inc's Operating Income amounts to -1.9B JPY.
What is Oncolys Biopharma Inc's Operating Income growth rate?
Operating Income CAGR 5Y
-9%
Over the last year, the Operating Income growth was -60%. The average annual Operating Income growth rates for Oncolys Biopharma Inc have been -5% over the past three years , -9% over the past five years .